This agreement enables the company to launch in the United States in the ... As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms our scientific strength and marks our ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

including without limitation EYLEA HD ® (aflibercept) Injection 8 mg; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new ...

Upon signature of the agreement, Klinge will receive upfront payments and is eligible to receive milestone payments on launch and sales ... and to add AHZANTIVE ® (aflibercept), a biosimilar to Eylea ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these ...

He also encouraged investors to “look beyond” Eylea, pointing instead to the launch of Dupixent in chronic obstructive pulmonary disease as well as several big data readouts that the pharma ...

AMGN)'s biosimilar Eylea product, Pavblu. This decision potentially allows Amgen to launch Pavblu at risk before the case is settled. Regeneron is actively working to mitigate the impact of ...

REGN filed an application with the FDA for the use of the Eylea HD pre-filled syringe (PFS). A potential approval and launch are expected by mid 2025. Longer-term data in wet age-related macular ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

including without limitation EYLEA HD® (aflibercept) Injection 8 mg; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s ...